References
- Papers of special note have been highlighted as:
- • of interest
- Acute lymphoblastic leukaemia (ALL) incidence trends over time. [cited 2015 Dec 9]. Available from: www.cancerresearchuk.org/.
- SEER Stat Fact Sheets: Acute Lymphocytic Leukemia (ALL). [cited 2015 Dec 9]. Available from www.seer.cancer.gov/statfacts/html/alyl.html.
- Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767.
- Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025–2037.
- Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–950.
• A key paper that showed in a 600 patient group how poor the outcome of relapse was
- Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–2041.
- Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic Leukemia. J Clin Oncol. 2014;32(36):4134–4140.
- Phase 3 Trial of Blinatumomab vs Investigator’s Choice of Chemotherapy in Patients With Relapsed or Refractory ALL, NCT020131. [ cited 2015 Dec 9]. Available from: www.clinicaltrials.gov.
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in Leukemia. NEJM. 2014;371:1507–1517.
- Pfizer. Inotuzumab ozogamicin Fact Sheet. 2012. [cited 2015 Dec 9]. Available from: www.pfizer.com/files/news/asco/inotuzumab_fact_sheet.pdf.
- Shah NN, Stevenson MS, Yuan CM,et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(6):964–969.
- DiJoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Cancer Res. 2006;12(1):242–249.
- Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085–2093.
- Kantarjian H, Thomas D, Jorgensen J. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–2736.
- Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–411.
• The phase 2 study that describes the remarkable efficacy data for inotuzamab in a subset of patients with advanced relapse.
- DeAngelo DJ, et al. Efficacy and Safety of Inotuzumab Ozogamicin vs Standard of care in salvage 1 or 2 patients with Acute Lymphblastic Leukaemia: an ongoing Global Phase 3 Study. Haematologica. 2015;100(S1):LB2073.
- Jabbour E, et al. Inotuzumab Ozogamicin in combination with low intensity chemotherapy (mini-hyper-CVAD) for the front line therapy in elderly patients (>60 years) with acute lymphoblastic leukaemia. Haematologica. 2015;100(S1):S114.
- Rytting M, Triche L, Thomas D. Initial experience with CMC544 (inotuzumab ozogamicin) in pediatric patients with relapsed B cell acute lymphoblastic leukemia. Pediatr Blood. 2014;544:369–372.
- A Study Of Inotuzumab Ozogamicin Versus Investigator’s Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia. NCT01564784. [cited 2015 Dec 9]. Available from: www.clinicaltrials.gov.
- Kebriaei P, Wilhelm K, Ravandi F, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13(3):296–301.
• Early data about allografting patients successfully treated with inotuzumab with insights into hepatotoxicity. This clearly requires study in a larger patient subset.
- Giles F, Kantarjian H, Kornblau S. MylotargTM(gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406–413.
- McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604.
- Wadleigh M, Richardson P, Zahrieh D. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell. Blood. 2003;102(5):1578–1582.
- Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–377.
- Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL), NCT01371630. [cited 2015 Oct 19]. Available from: www.clinicaltrials.gov.
- Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) NCT02311998. [cited 2015 Oct 19]. Available from: www.clinicaltrials.gov.
- Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia, NCT01925131. [cited 2015 Oct 19]. Available from: www.clinicaltrials.gov.
- CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies, NCT01664910. [cited 2015 Oct 19]. Available from: www.clinicaltrials.gov.